FDA Declines Approval of Summit Therapeutics' Ivonescimab for Advanced Lung Cancer
The U.S. Food and Drug Administration (FDA) has declined to approve Summit Therapeutics' drug ivonescimab when used in combination with chemotherapy for specific patients suffering from advanced lung cancer. The regulatory body cited a lack of sufficient evidence demonstrating that the treatment provides a meaningful survival benefit for this patient population. The decision introduces significant uncertainty regarding the commercial pathway and clinical development strategy for the therapy. As a key candidate in Summit's oncology pipeline, the rejection represents a setback for the company's efforts to expand its footprint in the lung cancer market.

Tickers: $SMMT
Topics: biotechnology drug approval FDA rejection lung cancer treatment
Read the full article at Seeking Alpha
Part of the story Summit Therapeutics Shares Drop Following FDA Rejection of Ivonescimab Combination Therapy (4 articles)